Incretin Atlas › Trials › DREAMS-3
DREAMS-3
Mazdutide · t2d
Design
- Molecule(s)
- Mazdutide
- Population
- t2d
- Official title
- A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Phase
- 3
- Registry status
- completed · 2024-02 → 2025-09
- Participants
- 349
- Duration
- 32 weeks
- Registry
- NCT06184568
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 mg vs semaglutide 1 mg: weight -6.0 %, HbA1c -1.84 | t2d china | 32 | 349 | — | —−10.3 % estimand not specified | −2.0 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (2)
- 6 mg · hba1c · press release
the mean change in HbA1c from baseline was −2.03% in the mazdutide group and −1.84% in semaglutide group
- 6 mg · weight_unsp · press release
the mean percentage weight reduction from baseline was 10.29% in the mazdutide group and 6.00% in the semaglutide group
Primary sources
- Innovent. Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 [press release]. 2025-10-26. Available from: https://www.prnewswire.com/news-releases/innovents-mazdutide-shows-superiority-in-glycemic-control-with-weight-loss-over-semaglutide-in-a-head-to-head-phase-3-clinical-trial-dreams-3-302594633.html
- ClinicalTrials.gov NCT06184568
How to cite this page
Medical Adviser's Group. Incretin Atlas: DREAMS-3. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/dreams-3/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.